125Ⅰ粒子植入联合化疗治疗非小细胞肺癌疗效观察

摘要

To evaluate the clinical efficacy of 125I seed implantation combined with chemotherapy in the treatrnment of patients with non-small cell lung carcinoma (NSCLC). The patients with NSCLC (n = 64) were rernceived interstitially 125I seed implantation by CT-guided, and then were treated with NVB and DDP after three rndays. In control group( n = 70), the patients were only treated with NVB and DDP. The therapeutic efficacy rnwas observed after two, four and six months. The results showed that the effective rates (CR + PR) after two, rnfour and six months of the treatment were 82.8％ , 90.6％ , 93.7％ , respectively. The effective rates in the rncontrol group were 4.4％ ,48.6％ ,52.9％ , respectively. The therapeutic effects had significant difference berntween two groups (P ＜0.05). There was a synergistic effect between 125i seed implantation and chemotherapy rnin patients with NSCLC to reduce tumor load in a short period and improve the therapeutic efficacy.%探讨125I粒子联合化疗治疗非小细胞肺癌(NSCLC)的临床疗效.采用CT引导下肿瘤内植入125I粒子,3 天后行长春瑞滨 (NVB)和 顺铂(DDP)静脉化疗,于2、4、6个月观察治疗效果(CR,PR,SD,PD).结果表明 125I粒子联合化疗组的有效率(CR+PR)分别为82.8%,90.6%,93.7%;单纯化疗组分别为44.3%,48.6%,52.9%,两组有显著性差异(P<0.05).NSCLC行125I粒子联合化疗具有协同作用,有利于短期内减轻肿瘤负荷,提高肿瘤疗效.